{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:48:17Z","timestamp":1761763697607},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6549,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1093\/annonc\/mdf017","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:59:57Z","timestamp":1027724397000},"page":"243-250","source":"Crossref","is-referenced-by-count":44,"title":["Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial"],"prefix":"10.1016","volume":"13","author":[{"given":"D.","family":"Pectasides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Glotsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bountouroglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kouloubinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mitakidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Karvounis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ziras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Athanassiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf017_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.45.1.8","article-title":"Cancer statistics, 1995","volume":"45","author":"Wingo","year":"1995","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdf017_bb0015","series-title":"Systemic chemotherapy of bladder cancer","first-page":"299","article-title":"Bladder Cancer: Biology and Management","author":"Sternberg","year":"1999"},{"key":"10.1093\/annonc\/mdf017_bb0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0025","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0022-5347(17)44167-X","article-title":"Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial","volume":"137","author":"Troner","year":"1987","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdf017_bb0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/JCO.1985.3.4.539","article-title":"Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract","volume":"3","author":"Khandekar","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/1097-0142(19830901)52:5<767::AID-CNCR2820520502>3.0.CO;2-P","article-title":"A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study","volume":"52","author":"Soloway","year":"1983","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0040","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ssu.2980080511","article-title":"Chemotherapy for urothelial tract malignancies: breaking the deadlock","volume":"8","author":"Scher","year":"1992","journal-title":"Semin Surg Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0045","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0050","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","article-title":"Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study","volume":"3","author":"Harker","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0055","first-page":"225","article-title":"NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network","volume":"12","author":"Scher","year":"1998","journal-title":"Oncology (Huntingt)"},{"key":"10.1093\/annonc\/mdf017_bb0060","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1999.17.8.2546","article-title":"Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma","volume":"17","author":"Dodd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0065","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0070","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0075","first-page":"633","article-title":"Chemotherapy for advanced bladder cancer","volume":"23","author":"Roth","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0080","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0085","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bjc.1998.681","article-title":"Docetaxel (Taxotere): an active agent in metastatic urothelial cancer: results of a phase II study in non-chemotherapy-pretreated patients","volume":"78","author":"De Wit","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/oxfordjournals.annonc.a058775","article-title":"Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study","volume":"5","author":"Pollera","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0095","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0100","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0105","first-page":"1208","article-title":"A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum","volume":"34","author":"Lorusso","year":"1998","journal-title":"Italian Co-operative Group on Bladder Cancer. Eur J Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","article-title":"Studies with RP-56976 (taxotere): a semisynthetic analogue of taxol","volume":"83","author":"Ringel","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf017_bb0115","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1008290406221","article-title":"Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)","volume":"8","author":"Vanhoefer","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0120","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.1994.12.8.1527","article-title":"Gemcitabine: current status of phase I and II trials","volume":"12","author":"Kaye","year":"1994","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdf017_bb0125","first-page":"67","article-title":"Phase II study of docetaxel (Taxotere) in patients with metastatic urothelial cancer","volume":"5","author":"De Wit","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(98)00150-2","article-title":"Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel","volume":"52","author":"Dimopoulos","year":"1998","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdf017_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0959-8049(97)84533-9","article-title":"Docetaxel and cisplatin (DC) combination chemotherapy for metastatic urothelial cancer","volume":"33","author":"Dimopoulos","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0140","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.1998.16.10.3392","article-title":"Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study","volume":"16","author":"Sengelov","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Abstr 1356","key":"10.1093\/annonc\/mdf017_bb0145","first-page":"19","article-title":"Phase II study of docetaxel (D) and cisplatin (CDDP) in advanced urothelial cancer. Preliminary results","volume":"345a","author":"Garcia del Muro","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0150","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1008331111654","article-title":"Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial","volume":"10","author":"von der Maase","year":"1999","journal-title":"Ann Oncol"},{"issue":"Abstr 1235","key":"10.1093\/annonc\/mdf017_bb0155","first-page":"17","article-title":"Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC). Final results of a phase II study","volume":"320a","author":"Kaufman","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1405","key":"10.1093\/annonc\/mdf017_bb0160","first-page":"35","article-title":"Gemcitabine\/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC). A phase II multicenter trial","volume":"347","author":"Mancarella","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0165","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.1999.17.9.2876","article-title":"Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"17","author":"Moore","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Abstr 1437","key":"10.1093\/annonc\/mdf017_bb0170","first-page":"19","article-title":"A phase II evaluation of gemcitabine plus docetaxel as therapy for advanced transitional cell carcinoma of the urothelium","volume":"364a","author":"Gitlitz","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0175","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.2000.18.18.3247","article-title":"Phase I\u2013II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group","volume":"18","author":"Bellmunt","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Abstr 1449","key":"10.1093\/annonc\/mdf017_bb0180","first-page":"19","article-title":"Gemcitabine, cisplatin and paclitaxel (GPT) in advanced transitional bladder cancer. Is there a schedule dependent clinical effect?","volume":"366a","author":"Frassoldati","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0185","series-title":"WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication","volume":"48","author":"World Health Organization","year":"1979"},{"key":"10.1093\/annonc\/mdf017_bb0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"17","key":"10.1093\/annonc\/mdf017_bb0195","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0200","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1994.12.11.2264","article-title":"Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group","volume":"12","author":"Roth","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0205","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/bjc.1997.106","article-title":"Phase II study of paclitaxel in pretreated patients with locally advanced\/metastatic cancer of the bladder and ureter","volume":"75","author":"Papamichael","year":"1997","journal-title":"Br J Cancer"},{"issue":"Abstr 1381","key":"10.1093\/annonc\/mdf017_bb0210","first-page":"19","article-title":"Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer","volume":"351a","author":"Broome","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0959-8049(93)90197-N","article-title":"Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer","volume":"29A","author":"Mahjoubi","year":"1993","journal-title":"Eur J Cancer"},{"issue":"Abstr 1230","key":"10.1093\/annonc\/mdf017_bb0220","first-page":"16","article-title":"Vinorelbine and paclitaxel in relapsed metastatic bladder carcinoma","volume":"344a","author":"Sobecks","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1429","key":"10.1093\/annonc\/mdf017_bb0225","first-page":"19","article-title":"Gemcitabine and vinorelbine combination in patients older than 70 years or unresponsive to cisplatin chemotherapy in advanced bladder cancer","volume":"362a","author":"Caristi","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 1431","key":"10.1093\/annonc\/mdf017_bb0230","first-page":"19","article-title":"Activity of pegylated liposomal doxorubicin (caelyx) in advanced transitional cell carcinoma (TCC)","volume":"363a","author":"Ernst","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0235","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0090-4295(91)80152-W","article-title":"Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study","volume":"38","author":"Crawford","year":"1991","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdf017_bb0240","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/jnci\/83.21.1582","article-title":"Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate","volume":"83","author":"Seligman","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf017_bb0245","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.1997.15.6.2449","article-title":"Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin and cisplatin in patients with advanced transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"issue":"Suppl 11","key":"10.1093\/annonc\/mdf017_bb0250","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitroand in vivo","volume":"22","author":"Peters","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0255","first-page":"5","article-title":"Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer","volume":"24","author":"Mattson","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0260","first-page":"825","article-title":"Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines","volume":"12","author":"Theodossiou","year":"1998","journal-title":"Int J Oncol"},{"issue":"Abstr 1389","key":"10.1093\/annonc\/mdf017_bb0265","first-page":"19","article-title":"Simultaneous and sequential combination schedules of gemcitabine and paclitaxel in human bladder cancer cell lines","volume":"353a","author":"Lindner","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0270","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1008344014518","article-title":"Is one cycle every three or four weeks obsolete? A critical review of dose-dense chemotherapy in solid neoplasms","volume":"11","author":"Fizazi","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf017_bb0280","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0959-8049(99)00187-2","article-title":"Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial","volume":"36","author":"Pectasides","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf017_bb0285","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","article-title":"Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer","volume":"19","author":"Hussain","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/2\/243\/19479589\/243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:29:16Z","timestamp":1582183756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419628085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0923753419628085"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf017","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}